Drugs / BAT2022
BAT2022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05518695 | Jun → Nov 2022 | COVID-19 | Bio-Thera Solutions | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT2022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05518695 ↗ |
| Known as | BAT2022 for Injection (bispecific neutralizing antibody targeting the receptor binding domain (RBD) of spike of SARS-CoV-2) | “BAT2022 for Injection (bispecific neutralizing antibody targeting the receptor binding domain (RBD) of spike of SARS-CoV-2)” NCT05518695 ↗ |
| Action | Inhibit | “bispecific neutralizing antibody targeting the receptor binding domain (RBD) of spike of SARS-CoV-2” NCT05518695 ↗ |
| Route | Intravenous | “single intravenous injection of BAT2022 for Injection” NCT05518695 ↗ |